89bio(ETNB) - 2024 Q2 - Quarterly Results

Exhibit 99.1 89bio Reports Second Quarter 2024 Financial Results and Corporate Updates –The Phase 3 ENLIGHTEN-Fibrosis trial in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and the Phase 3 ENLIGHTEN-Cirrhosis trial in patients with compensated cirrhosis (F4) are enrolling patients– –Phase 3 ENTRUST trial for patients with severe hypertriglyceridemia (SHTG) continues to enroll patients and topline data is expected in 2025– SAN FRANCISCO, August 5, 2024 (GLOBE NEWSWIRE) ...